Vitruvian Partners LLP Purchases New Position in RxSight, Inc. (NASDAQ:RXST)

Vitruvian Partners LLP bought a new position in shares of RxSight, Inc. (NASDAQ:RXST) during the 4th quarter, according to its most recent 13F filing with the SEC. The firm bought 144,300 shares of the company’s stock, valued at approximately $4,961,000. RxSight accounts for approximately 4.3% of Vitruvian Partners LLP’s holdings, making the stock its 5th largest position. Vitruvian Partners LLP owned approximately 0.36% of RxSight as of its most recent filing with the SEC.

Several other hedge funds have also recently bought and sold shares of RXST. RA Capital Management L.P. lifted its holdings in shares of RxSight by 6.0% during the third quarter. RA Capital Management L.P. now owns 3,916,825 shares of the company’s stock worth $193,609,000 after buying an additional 222,000 shares in the last quarter. State Street Corp lifted its holdings in shares of RxSight by 8.3% during the third quarter. State Street Corp now owns 817,671 shares of the company’s stock worth $40,417,000 after buying an additional 62,349 shares in the last quarter. Geode Capital Management LLC lifted its holdings in shares of RxSight by 17.7% during the third quarter. Geode Capital Management LLC now owns 817,117 shares of the company’s stock worth $40,398,000 after buying an additional 122,775 shares in the last quarter. Point72 Asset Management L.P. lifted its holdings in shares of RxSight by 610.2% during the third quarter. Point72 Asset Management L.P. now owns 446,976 shares of the company’s stock worth $22,094,000 after buying an additional 384,041 shares in the last quarter. Finally, Thrivent Financial for Lutherans lifted its holdings in shares of RxSight by 53.6% during the fourth quarter. Thrivent Financial for Lutherans now owns 352,626 shares of the company’s stock worth $12,124,000 after buying an additional 122,989 shares in the last quarter. 78.78% of the stock is currently owned by institutional investors and hedge funds.

Insider Transactions at RxSight

In related news, Director Jesse Anderson Corley bought 1,443 shares of RxSight stock in a transaction that occurred on Wednesday, January 15th. The shares were acquired at an average cost of $31.18 per share, for a total transaction of $44,992.74. Following the completion of the acquisition, the director now directly owns 1,443 shares of the company’s stock, valued at approximately $44,992.74. The trade was a ∞ increase in their position. The purchase was disclosed in a document filed with the SEC, which is available at the SEC website. Also, Director Tamara Fountain sold 7,000 shares of the company’s stock in a transaction that occurred on Wednesday, March 12th. The shares were sold at an average price of $25.71, for a total value of $179,970.00. Following the completion of the sale, the director now owns 24,793 shares in the company, valued at $637,428.03. The trade was a 22.02 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Company insiders own 9.36% of the company’s stock.

Analyst Upgrades and Downgrades

A number of equities research analysts have recently weighed in on the company. Bank of America dropped their target price on RxSight from $60.00 to $36.00 and set a “buy” rating for the company in a report on Friday. JPMorgan Chase & Co. dropped their price target on RxSight from $62.00 to $40.00 and set an “overweight” rating for the company in a research note on Wednesday, February 26th. Stifel Nicolaus dropped their price target on RxSight from $33.00 to $28.00 and set a “hold” rating for the company in a research note on Wednesday. Wells Fargo & Company dropped their price target on RxSight from $40.00 to $35.00 and set an “equal weight” rating for the company in a research note on Wednesday, February 26th. Finally, Needham & Company LLC reaffirmed a “buy” rating and issued a $43.00 price target on shares of RxSight in a research note on Wednesday, February 26th. Two analysts have rated the stock with a hold rating and seven have issued a buy rating to the company’s stock. According to MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $49.33.

RxSight Stock Down 0.2 %

RxSight stock opened at $24.84 on Friday. The stock has a market cap of $1.01 billion, a PE ratio of -29.93 and a beta of 1.22. The business’s 50-day moving average price is $29.63 and its two-hundred day moving average price is $40.05. RxSight, Inc. has a 12-month low of $24.09 and a 12-month high of $66.54.

RxSight (NASDAQ:RXST) last released its quarterly earnings results on Tuesday, February 25th. The company reported ($0.15) earnings per share for the quarter, missing the consensus estimate of $0.10 by ($0.25). The firm had revenue of $40.21 million for the quarter, compared to the consensus estimate of $40.23 million. RxSight had a negative return on equity of 14.00% and a negative net margin of 23.92%. As a group, analysts expect that RxSight, Inc. will post -0.7 earnings per share for the current year.

RxSight Company Profile

RxSight, Inc, a commercial-stage medical device company, engages in the research and development, manufacture, and sale of light adjustable intraocular lenses (LAL) used in cataract surgery in the United States and internationally. It offers RxSight system that enables doctors to customize and enhance the visual acuity for patients after cataract surgery.